文章
醫療新知 > 新療法 : 結合Tyverb及標靶藥Herceptin兩款藥物治療Her2乳癌

新療法 : 結合Tyverb及標靶藥Herceptin兩款藥物治療Her2乳癌

11-03-2016

 

Drug combination shrinks HER2 positive breast

 

cancers within 11 days

 

A drug combination – of lapatinib and trastuzumab (Herceptin) – before surgery shrinks and may even destroy tumours in women with HER2 positive disease within 11 days. The results are from a Cancer Research UK-funded trial* being presented at the 10th European Breast Cancer Conference (EBCC10)(link is external) today.

The research may lead to fewer women needing chemotherapy.

“These results are very promising if they stand up in the long run and could be the starting step of finding a new way to treat HER2 positive breast cancers." – Professor Arnie Purushotham, senior clinical adviser at Cancer Research UK

The EPHOS B trial, led by researchers at The Institute of Cancer Research, London, the University of Manchester and University Hospital of South Manchester NHS Foundation Trust, studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.

In the trial, women were split into three groups and treated for 11 days before their surgery. Initially women were randomised to receive either trastuzamab, or lapatinib or no treatment – but halfway through the trial after evidence from other trials of the effectiveness of the combination the design was altered so that additional women allocated to the lapatinib group were also prescribed trastuzumab.

The trial set out to study the biological effects of the drug combination by measuring biological markers of cellular proliferation after 11 days of therapy. But when trying to measure this, the researchers discovered that in roughly a quarter of the 66 women who received both drugs the remaining tumour was too small for the second measurement of cell proliferation.

17 per cent of the women receiving both drugs had only minimal residual disease – defined as an invasive tumour smaller than 5mm in size – and 11 per cent had a pathological complete response – meaning no biological sign of invasive tumour could be found in the breast.

Three per cent of the women treated with trastuzumab only had residual disease or complete response.

HER2 positive breast cancer is more likely to come back after treatment than some other types of breast cancer. It is generally treated with surgery, chemotherapy, endocrine therapy and targeted anti-HER2 drugs.

Around 53,400 women are diagnosed with invasive breast cancer – with about 10-15 per cent of these characterised as HER2 positive breast cancer – and around 11,600 women die  from the disease in the UK every year.

Current treatments are effective, and complete response is common after three to four months, but the researchers say observing a disease response after 11 days was very surprising.

Trial co-leader Professor Judith Bliss, director of the Cancer Research UK-funded clinical trials and statistics unit at The Institute of Cancer Research, London, said: “Our trial set out to try to use the window between diagnosis and surgery to find clues that combined treatment with trastuzumab and lapatinib was having a biological effect on HER2 positive tumours. So it was unexpected to see quite such dramatic responses to the trastuzumab and lapatinib within 11 days.

“Our results are a strong foundation on which to build further trials of combination anti-HER2 therapies prior to surgery – which could reduce the number of women who require subsequent chemotherapy, which is also very effective but can lead to long-term side effects.”

Clinical chief investigator and trial co-leader Professor Nigel Bundred, professor of surgical oncology at The University of Manchester and clinical consultant at University Hospital of South Manchester NHS Foundation Trust, said: “These early and significant tumour regressions seen on dual anti-HER2 therapy suggest that we will be able to personalise treatment for these cancers on the basis of early response, allowing us to identify patients who in the future may avoid treatment morbidity or avoid chemotherapy”.

Professor Arnie Purushotham, senior clinical adviser at Cancer Research UK, said: “These results are very promising if they stand up in the long run and could be the starting step of finding a new way to treat HER2 positive breast cancers. This could mean some women can avoid chemotherapy after their surgery – sparing them the side-effects and giving them a better quality of life.”

Cancer Research UK scientists helped establish the link between some cancers and ‘growth factor receptor’ proteins on the surface of cells – a crucial early step in the development ofHerceptin. Cancer Research UK also funded the clinical trials unit where the research showing that Herceptin can improve survival for people with a certain type of breast cancer was completed.


www.cancerresearchuk.org/about-us/cancer-news/press-release/2016-03-10-drug-combination-shrinks-her2-positive-breast-cancers-within-11-days

———————————————————

 

【治乳癌突破】結合兩種藥醫治 腫瘤最快11日消失


英國發現一種新的乳癌療法,在病人確診後立即給予兩種現有的藥物治療,最快可以在11天之內令腫瘤消失,有醫生甚至形容,未曾見過乳癌病人這麼快就對療程產生反應。

 

新療法由曼徹斯特大學和倫敦的癌症研究學院(Institute of Cancer Research)發現,研究團隊結合泰康達(Tyverb)及標靶藥Herceptin兩款乳癌藥物,向新確診病人立即用藥,原本是希望病人的腫瘤在手術前縮小,後來卻發現有些腫瘤在動手術前已消失。

 

研究在英國23間醫院進行,涉及257名新病人。接受新療法的66名患者中,87%對療法有反應,腫瘤停止產生更多癌細胞,令癌細胞數目下降。11%的患者的腫瘤更已經消失,另外17%病人的腫瘤明顯縮小至直徑少於5毫米。而病人的腫瘤原本直徑達3厘米。

 

帶領研究的曼徹斯特大學癌症外科醫生邦德雷德(Nigel Bundred)非常興奮,稱:「實體腫瘤在11天之內消失是聞所未聞,這些都是令人難以置信的結果。」研究的詳情在阿姆斯特丹的歐洲乳癌會議上公佈。

 

這個療法是針對難纏的HER2型乳癌,雖然患病女性仍需要接受手術確保癌細胞全部消失,但醫生希望這個方法可以令她們免卻化療之苦。

 

英國《每日郵報》/《每日電訊報》


hk.apple.nextmedia.com/realtime/international/20160311/54854039

疑難排解

會員註冊


或許你會想看
科技園創科社群逾30創新醫療方案 亮相醫療健康周吸引投資者目光
  科技園創科社群逾30創新醫療方案  亮相醫療健康周吸引投資者目光 公開亮相包括癌症測試及心血管疾 […]
「1+」新機制 兩治癌新藥准在港註冊
特區政府推出「1+」新藥審批機制實施後,已有兩款癌症新藥獲批准在香港註冊,讓更多本地病人受惠。醫院管理局表示, […]
政府延續「支援粵港澳大灣區醫院管理局病人先導計劃」至明年三月底
醫務衞生局(醫衞局)今日(三月七日)公布,「支援粵港澳大灣區醫院管理局病人先導計劃」(先導計劃)會延續至明年三 […]
【醫學研究】港大醫學院研究顯示太極有效改善晚期肺癌患者睡眠質素
晚期肺癌患者睡眠障礙及心理症狀 影響整體存活率 肺癌一直是香港最常見的癌症,亦是主要的癌症死因。晚期肺癌患者長 […]
FDA批准首個靶向HER2陽性跨癌種治療藥Enhertu
近日,美國FDA批准了一款針對轉移性HER2陽性實體瘤的靶向藥物,這意味著該類患者無論是哪種癌症類型以及癌細胞 […]
【中西醫協作】醫務衞生局委任中醫藥發展專員
醫務衞生局(醫衞局)今日(四月十日)宣布,經公開招聘後,委任鍾志豪博士為中醫藥發展專員。任期由二○二四年五月二 […]
【癌症研究】中大醫學院研究應對肝癌免疫治療的抗藥性
原發性肝癌是全球第四大及香港第三大致命癌症。2021年,本港有超過1,400人死於肝癌。對於無法進行切除腫瘤手 […]
【癌症治療】綠葉製藥創新葯在港澳門上市 小細胞肺癌二線治療迎來新突破
2024年3月7日,中國香港&中國澳門——由香港腫瘤治療學會主辦、綠葉製藥集團支持的“小細胞肺癌(SC […]
【醫學研究】中大研究發現咽峽炎鏈球菌可引致胃癌
香港中文大學(中大)醫學院最新研究發現一種名為「咽峽炎鏈球菌」(Streptococcus anginosus […]
【醫學研究】癌症治療新突破:港大醫學院研製雙重抗腫瘤疫苗
香港大學李嘉誠醫學院(港大醫學院)的研究團隊發現,從 γδ-T 細胞中提取的外泌體不僅具有直接的抗腫瘤效果,在 […]
【大灣區醫療】首間港資深圳私人綜合醫院 盼縮短港人治療輪候時間 |深圳新風和睦家醫院介紹
本港公營醫療服務供不應求,導致病人長期輪候成常態。近期港人流行「北上消費」,除了吃喝玩樂,「北上醫療」亦是「北 […]
【大灣區醫療】深圳新風和睦家醫院與保誠保險簽署跨境保險業務合作,進一步拓展大灣區醫療網絡服務
深圳新風和睦家醫院(以下簡稱「和睦家」)與保誠保險有限公司(以下簡稱「保誠」)今日簽署戰略性的直接合作,保誠成 […]